Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
株式のランク #17309
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
株価
$1.21
時価総額
$248.41M
変化(1日)
4.11%
変化(1年)
79.12%
TW
取引 TWi Biotechnology, Inc. (6610)

カテゴリー

TWi Biotechnology, Inc.(6610)の株式分割履歴
TWi Biotechnology, Inc.株(シンボル:6610)は合計で0回の株式分割を実施しました。
最新の株式分割はSep 02, 2026に行われました。
Sep 02, 2026より前に購入された6610株は、現在06610株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH